Ascension Health Ventures

HOME

ABOUT AHV

PORTFOLIO COMPANIES

LIMITED PARTNERS

NEWS

Monday, February 08, 2010

Ascension Health Ventures, LLC (AHV)

AHV closes second fund, CHV II, L.P., at $200 million.
A strategic healthcare venture fund focused on the medical device, technology and service sectors. Established within Ascension Health, to invest in the future of its 400 year legacy, AHV’s role is to construct and manage a strategic portfolio of investments that deliver a venture investment return, have the potential to transform the healthcare industry and significantly enhance the quality of patient care. With our second fund, this vision and the potential impact will be extended to our limited partners, Catholic Health Initiatives, Catholic Health East, and Catholic Healthcare West.

Augmenix Closes $6.1 M Financing
Ascension Health Ventures led a $6.1 million Series B financing in Augmenix. Augmenix is a medical device company developing in-situ formed, space-filling hydrogels sepcifically for radiation oncology and cancer surgery indications.

AHV Invests in Haven Behavioral Healthcare
Nashville, Tennessee, June 2008 – Haven Behavioral Healthcare (“Haven”) a leading provider of specialty behavioral health services, announced that Ascension Health Ventures (“AHV”) has made an equity investment in the Company, joining existing investors Thoma Cressey Bravo, Clayton Associates and Haven management as shareholders. AHV is the general partner of CHV II, L.P., an investment fund formed by Ascension Health, Catholic Health Initiatives, Catholic Health East and Catholic Healthcare West.

BioImagene Closes $26 M Series D Financing Round
BioImagene, the leading provider of innovative digital pathology solutions for preclinical research and cancer diagnosis, today announced the closing of a $26 million series D financing round led by Burrill & Company. Ascension Health Ventures, National Healthcare Services and existing investors Artiman Ventures and ICCP Ventures also joined the round with strong support.

| | |